Pharmaceuticals

Actemra (Tocilizumab) Market Growth Patterns And Forecast Outlook Through 2030

May 5, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Actemra (Tocilizumab) Market Progress Between 2026 And 2030?

The market size for actemra (tocilizumab) has experienced rapid growth in recent years. It is projected to increase from $5.71 million in 2025 to $6.32 million in 2026, maintaining a compound annual growth rate (CAGR) of 10.6%. This past growth can be attributed to the recognized function of IL-6 in inflammation, the rising prevalence of rheumatoid arthritis, strong clinical trial results, the adoption of biologics in tertiary hospitals, and regulatory approvals spanning various indications.

The actemra (tocilizumab) market is expected to experience significant growth in the coming years. Its size is projected to reach $9.34 million by 2030, demonstrating a compound annual growth rate (CAGR) of 10.3%. This anticipated expansion during the forecast period is attributed to factors such as an increasing burden of autoimmune diseases, the extension of its use into new inflammatory indications, the growth of biologic infusion centers, improved early diagnosis rates, and enhanced access to biologic therapies. Major trends identified for the forecast period include a broader application in autoimmune and inflammatory disorders, a rising adoption in the management of cytokine release syndrome, an increase in hospital-based biologic administration, a heightened focus on early IL-6 targeted intervention, and improved long-term safety monitoring for biologics.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19849&type=smp

Which Major Drivers Are Influencing The Expansion Of The Actemra (Tocilizumab) Market?

The increasing occurrence of rheumatoid arthritis is anticipated to boost the actemra (tocilizumab) market. Rheumatoid arthritis is a long-term autoimmune disorder characterized by joint inflammation, damage, and a diminished quality of life for millions worldwide. Its development is influenced by elements like smoking, obesity, environmental factors, and hormonal imbalances. Actemra (tocilizumab) serves as a treatment for rheumatoid arthritis, working to lessen inflammation and avert joint deterioration by blocking the interleukin-6 (IL-6) receptor, especially beneficial for individuals unresponsive to alternative therapies. For instance, data from April 2024, released by the National Institute for Health and Care Research (NIHR), a UK government agency, indicated that around 700,000 people in the UK suffer from rheumatoid arthritis. Furthermore, a June 2024 report by the Australian Institute of Health and Welfare, an Australia-based national agency, stated that approximately 514,000 people (2.0% of the population) in Australia had rheumatoid arthritis in 2022. In 2023, this condition represented 2.0% of the overall disease burden and 16% of the burden specifically for musculoskeletal conditions. Moreover, rheumatoid arthritis contributed to 1,322 deaths in 2022, corresponding to 5.1 deaths per 100,000 people and accounting for 0.7% of all fatalities. Consequently, the increasing incidence of rheumatoid arthritis is a key driver for the actemra (tocilizumab) market.

Which Segment Classifications Are Used In The Actemra (Tocilizumab) Market Segment Analysis?

The actemra (tocilizumab) market covered in this report is segmented –

1) By Product Type: Min Purity Less Than 98%, Min Purity 98%-99%, Min Purity More Than 99%

2) By Dosage: Injection, Solution, Concentrate

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By Application: Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), Rheumatoid Arthritis (RA)

Which Trends Are Guiding The Direction Of The Actemra (Tocilizumab) Market?

Key companies active in the actemra (tocilizumab) market are focusing on developing advanced solutions, such as tocilizumab biosimilar, to gain a competitive edge in the sector. Tocilizumab biosimilars are approved for treating autoimmune diseases and COVID-19, providing an alternative to the originator drug Actemra. For instance, in November 2023, Fresenius Kabi, a Germany-based healthcare company, launched Tyenne, the first tocilizumab biosimilar referencing RoActemra (tocilizumab) in the European Union. Tyenne is approved for the treatment of multiple inflammatory and immune diseases, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, cytokine release syndrome (CRS), and COVID-19.

Which Firms Are Contributing To The Actemra (Tocilizumab) Market Ecosystem?

Major companies operating in the actemra (tocilizumab) market are Roche Holding AG, Fresenius Kabi

Get The Full Actemra (Tocilizumab) Market Report:

https://www.thebusinessresearchcompany.com/report/actemra-tocilizumab-global-market-report

Which Region Is The Largest In The Actemra (Tocilizumab) Market?

North America was the largest region in the actemra (Tocilizumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the actemra (tocilizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Actemra (Tocilizumab) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/actemra-tocilizumab-global-market-report

Browse Through More Reports Similar to the Global Actemra (Tocilizumab) Market 2026, By The Business Research Company

Tofacitinib Market Report 2026

https://www.thebusinessresearchcompany.com/report/tofacitinib-global-market-report

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795